When a clinician first named what was happening to my body, the moment felt clinical and oddly intimate at once. Under a bright exam light I was told it was vaginal atrophy, which I later learned is the thinning and drying of the vaginal lining. Before that appointment I had chalked recurring pain during urination and discomfort when I tried to bottom up to simple urinary tract infections or poor lubrication. The medical label didn’t erase the embarrassment of the exam, but it did give a precise term to a condition that had been shrinking my options for sexual pleasure and comfort.
At the time of diagnosis I was thirty and had been taking testosterone for five years. The realization that a medication I relied on for gender affirmation could cause an anatomical change that limited intimacy felt like a blow. I cycled through frustration, anger, and practical steps: searching online, talking to a therapist, and pushing my provider for options. That search highlighted how sexual function and gender transition are tightly interwoven — decisions about hormones ripple into partners, positions, and the ways we imagine pleasure.
How a diagnosis ripples through identity and sex
My sexual history wasn’t linear. For years I tried to inhabit a cis feminine role and avoided sex altogether out of insecurity. Later I performed as a stud; social pressure and peer expectations meant I almost always topped. In that era, taking on a receptive role was policed by peers as being “too gay,” a phrase that masked internalized homophobia and rigid gender roles. Only after I recognized myself as nonbinary and trans did my sexual life broaden: partners of different genders, experimenting with positions, and learning I could experience pleasure given to me rather than only self-generated. Losing the ability to bottom because of vaginal atrophy felt like someone taking back a right I had just won.
Why care and research often miss the mark
One reason this feels like an avoidable harm is the research gap. Much of the scientific literature on vaginal atrophy focuses on cis women during menopause or people undergoing certain cancer treatments, not on people assigned female at birth who are using testosterone. Organizations like Folx Health note that thinning and dryness of the vaginal lining are common in trans men, trans masculine people, and other AFAB nonbinary or intersex folks on HRT, yet guidelines and studies rarely center their experiences. That gap leaves patients underinformed, clinicians improvising care, and communities trading tips in informal networks rather than relying on robust, inclusive evidence.
Consequences of uneven care
The practical fallout is real: people start hormones without a clear discussion of sexual side effects, some receive misguided clinical advice, and many rely on community-sourced remedies. Access compounds the problem. I’m fortunate to see a provider at an LGBTQ+-focused clinic that understands trans gynecologic health, but that privilege is fragile. In many parts of the country, where trans healthcare is politically contested and services are being defunded or stigmatized, finding a competent clinician can be nearly impossible. That geographical and structural variability is a public health failure for sexual well-being.
Treatment choices, resilience, and the path forward
After diagnosis I began a low-dose course of estrogen for the atrophy and have noticed improvements. That treatment choice didn’t negate the value of my transition; I remain committed to living in a body that aligns with my gender. But the broader point stands: no one should have to pick between gender affirmation and sexual fulfillment. Clinicians need to counsel patients about potential effects of hormone therapy, and researchers must design studies that include trans, nonbinary, and intersex people so care recommendations reflect lived realities.
A plea for inclusive research and care
The personal stakes are intimate: sexual desire, the ability to consent fully to certain acts, and simple bodily autonomy. The collective stakes are structural: equitable access to knowledgeable providers, clear patient information, and evidence-based treatments tailored to diverse bodies. I’ve regained some function and pleasure with medical support, but many people still navigate this terrain alone. We need research that centers our experiences and a healthcare system that recognizes the intersection of gender, hormone therapy, and sexual health so everyone can pursue pleasure and well-being without trade-offs.